CSF p-tau217 levels reflect a dynamic equilibrium between neuronal tau release and CSF clearance, with significant inter-individual variability in turnover rates. Baseline-adjusted p-tau217 normalization (personal threshold = individual baseline × treatment-responsive decline trajectory) would more accurately predict when pathology-driven tau phosphorylation has ceased. However, CSF p-tau217 half-life has not been directly measured in humans, and assay variance dominates at low concentrations where personalization is most needed.
Curated pathway from expert analysis
flowchart TD
A["CSF p-tau217<br/>Biomarker Level"]
B["Individual Baseline<br/>Variability in Half-Life"]
C["CST3 Cystatin C<br/>Degradation Rate Modulator"]
D["AQP4 Water Channel<br/>CSF Turnover Rate"]
E["Personalized Cessation<br/>Threshold"]
F["p-tau217 Monitoring<br/>Precision Adjusted"]
G["Biomarker-Guided<br/>Therapeutic Stopping Point"]
A --> B
B --> C
B --> D
C --> E
D --> E
E --> F
G -.->|"defines"| E
style A fill:#7b1fa2,stroke:#ce93d8,color:#ce93d8
style F fill:#1b5e20,stroke:#a5d6a7,color:#a5d6a7No linked papers recorded for this hypothesis yet.
No curated PDB or AlphaFold mapping for CST3 yet. Search RCSB →
Median TPM across 13 brain regions for CST3, AQP4 from GTEx v10.
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for CST3, AQP4.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
No resource usage or linked notebooks recorded for this hypothesis yet.
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF personalized cessation thresholds are defined as individual baseline p-tau217 concentration multiplied by the treatment-responsive decline trajectory (calculated as % change from baseline at month | Personalized threshold group will show significantly lower rates of biomarker re-elevation (≤10%) compared to fixed threshold group (≥25%) during the 12-month o | — no observation — | pending | 0.48 |
| IF participants with Alzheimer's disease receiving anti-tau immunotherapy are stratified by individual baseline p-tau217 half-life (short <14 days vs. long >28 days, assessed via stable isotope labeli | Participants with longer baseline p-tau217 half-life will demonstrate 40-60% slower decline rates in CSF p-tau217 levels and reach the normalization threshold 5 | — no observation — | pending | 0.55 |